Allergan

Envy Medical is a biotechnology company specializing in dermatology and medical aesthetics solutions. It focuses on developing non-invasive skin rejuvenation therapies aimed at patients with various dermatological conditions. The company utilizes dermal infusion techniques combined with advanced skincare products that contain effective ingredients to address issues such as hyperpigmentation, aging, and acne. Through its innovative approaches, Envy Medical enables customers to enhance and maintain their skin health and appearance. As of March 2019, Envy Medical operates as a subsidiary of Allergan plc.

Bonti, Inc. is a biotechnology company focused on developing neurotoxin products for both aesthetic and therapeutic uses. The company specializes in botulinum neurotoxin serotype E, offering two primary products: EB-001A for aesthetic applications and EB-001T for therapeutic indications. Bonti aims to provide solutions for patients experiencing muscle hyperactivity and associated musculoskeletal pain, addressing unmet medical needs with a long-acting, non-opioid local muscle relaxant that minimizes side effects common with existing treatments. Founded in 2015, Bonti was originally known as Endurance Biotech, Inc. and changed its name in August 2015. The company is headquartered in Newport Beach, California, and operates as a subsidiary of Allergan plc.

Elastagen is a clinical-stage medical company focused on developing products based on human protein tropoelastin, a vital component for tissues that require elasticity, such as skin and blood vessels. The company has created a synthetic version of elastin that mirrors the natural protein found in the human body, allowing for innovative applications in skin rejuvenation, scar remodeling, and tissue repair. Elastagen's offerings include injectable synthetic human elastin and chemically cross-linked tropoelastin for aesthetic purposes, aimed at helping patients maintain skin elasticity and suppleness. Founded through the acquisition of intellectual property from research conducted by Prof Weiss at the University of Sydney, Elastagen has attracted significant investment from both Australian and international life science venture capital groups. Its operations have grown from Australia to include production facilities in Europe and clinical activities in the UK.

Repros Therapeutics Inc. ® was organized on August 20, 1987. We are a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

Zeltiq Aesthetics, Inc. is a medical technology company founded in 2005 and headquartered in Pleasanton, California. It specializes in the development and commercialization of non-invasive products aimed at the selective reduction of fat. The company's flagship product, the CoolSculpting system, employs a patented method known as Cryolipolysis, which utilizes precisely controlled cooling to target and eliminate stubborn fat cells without damaging surrounding tissue. This FDA-cleared device is designed for various applications in dermatologic treatments and is marketed primarily to dermatologists, plastic surgeons, and aesthetic specialists across North America, the Asia-Pacific, Europe, and Latin America. Zeltiq Aesthetics was formerly known as Juniper Medical, Inc. and rebranded in July 2007. As of 2017, it operates as a subsidiary of Allergan plc.

Lysosomal Therapeutics, Inc. is a biotechnology company focused on discovering and developing small-molecule therapies for severe neurological diseases. Founded in 2011 and based in Cambridge, Massachusetts, the company targets disorders such as Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies. Lysosomal Therapeutics employs a unique molecular platform informed by the clinically validated connection between lysosomal disorders and neurodegeneration. This approach facilitates the development of innovative treatment options aimed at improving the health and quality of life for patients affected by these debilitating conditions.

LifeCell Corporation, founded in 1986 and based in Branchburg, New Jersey, specializes in the development and marketing of tissue repair products for various surgical procedures. The company's portfolio includes Strattice Reconstructive Tissue Matrix and AlloDerm Regenerative Tissue Matrix, used in plastic, reconstructive, general surgical, burn, and periodontal procedures; Cymetra Regenerative Tissue Matrix, suitable for injection; and Repliform Regenerative Tissue Matrix for urogynecologic surgeries. Additionally, LifeCell offers GraftJacket for orthopedic procedures and AlloCraft DBM for bone grafting. The company's products are utilized in applications such as abdominal wall reconstruction, hernia repair, breast reconstruction, and ENT/head and neck plastic reconstruction. LifeCell distributes its products to patients and healthcare professionals through various channels both domestically and internationally.

Chase Pharmaceuticals Corporation is a specialty pharmaceutical company established in 2007 and headquartered in Washington, D.C. The company is dedicated to developing innovative medications aimed at treating Alzheimer's disease and related neurodegenerative disorders. Its primary product, CPC-252, is a transdermal formulation designed for managing the symptoms of Alzheimer's and Parkinsonism dementia. Chase Pharmaceuticals focuses on identifying and advancing promising treatments for central nervous system diseases, with a goal of addressing the significant unmet medical need in neuropsychiatry, particularly with Alzheimer’s disease, which is recognized as a major public health challenge. The company operates by selecting and developing product candidates that can be licensed to commercial partners, thus contributing to its strategic aim of improving the quality of life for those affected by cognitive decline. With an increasing global population affected by Alzheimer's and escalating healthcare costs, Chase Pharmaceuticals is positioned to play a crucial role in the development of more effective therapies for this condition.

Motus Therapeutics is a biotechnology company located in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet needs in metabolic diseases. The company specializes in treatments for gastrointestinal disorders, with its lead product candidate, relamorelin, acting as a ghrelin agonist. Relamorelin is specifically designed for the treatment of diabetic gastroparesis, a gastrointestinal complication associated with diabetes, as well as other gastrointestinal functional disorders. Through its innovative approach, Motus Therapeutics aims to improve the quality of life for patients suffering from these conditions.

Tobira Therapeutics, Inc. is a biotechnology company based in Princeton, New Jersey, focused on the research, development, and commercialization of antiviral compounds aimed at addressing life-threatening infectious diseases. Founded in 2006, the company specializes in developing TBR-652 and TBR-220 antagonists specifically for the treatment of HIV/AIDS and hepatitis, along with other related infectious conditions. Through its innovative approach, Tobira Therapeutics seeks to provide effective therapies for patients suffering from these serious health challenges.

Akarna Therapeutics Ltd. is a biopharmaceutical company focused on developing small molecule therapeutics for inflammatory and fibrotic diseases. Established in 2014, the company operates out of offices in Cambridge, United Kingdom, and San Diego, California. Akarna's lead program centers on a non-bile acid FXR agonist, which aims to provide a best-in-class therapeutic option for treating nonalcoholic steatohepatitis (NASH), a severe form of fatty liver disease with no currently approved treatments. At present, the lead candidate is undergoing preclinical studies, including IND-enabling toxicology and safety pharmacology assessments, with plans to initiate first-in-human trials.

Vitae Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Fort Washington, Pennsylvania, that specializes in discovering and developing novel small molecule drugs aimed at addressing significant unmet medical needs. Founded in 2001, Vitae's product pipeline includes VTP-43742, currently in Phase I clinical trials for autoimmune disorders such as psoriasis and multiple sclerosis, and VTP-38543, which is in Phase IIa trials for atopic dermatitis. The company is also advancing VTP-34072 in Phase II trials for type 2 diabetes and VTP-38443 for acute coronary syndrome, as well as BI 1147560 for Alzheimer's disease. Vitae Pharmaceuticals utilizes a structure-based drug-design platform known as Contour to develop its compounds, targeting large markets with chronic conditions, including chronic kidney disease and atherosclerosis. In 2016, Vitae became a subsidiary of Allergan plc.

RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. Founded in 2009, RetroSense Therapeutics is headquartered in Ann Arbor, Michigan.

ForSight VISION5, founded in 2010 as part of ForSight Labs, specializes in the development of non-invasive drug delivery technologies aimed at treating major eye diseases such as glaucoma, dry eye, and allergies. The company is focused on creating innovative products that can replace traditional eye drops and offer sustained therapeutic effects. Currently, ForSight VISION5 is advancing its lead product, the Helios insert, which is undergoing its second Phase 2 clinical study, reflecting the company's commitment to improving patient care in ophthalmology through effective and patient-friendly solutions.

Allergan is a $23 billion diversified global pharmaceutical company and a leader in a new industry model - Growth Pharma. The company is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team creating an unrivaled foundation for long-term growth. Driving continued innovation and growth is the combined company’s strong commitment to R&D, with an investment of ~$1.7 billion in 2015, focused on strategic development of innovative and durable value-enhancing products within brands, generics, biologics and OTC portfolios. The Company’s Generics portfolio features more than 1,000 generics, branded generics, established brands and OTC products. The Company is the third largest generic manufacturer in the U.S. and holds a top 5 leadership position in nearly 20 International markets. Allergan has global headquarters in Dublin, Ireland and U.S. Administrative Headquarters in Parsippany, New Jersey, USA.

Anterios Inc. is a clinical-stage biopharmaceutical company based in New York, New York, specializing in the development of innovative drug delivery systems utilizing nanotechnology. Originally known as Encapsion Inc., the company focuses on creating next-generation botulinum-based prescription products for therapeutic and aesthetic applications. Since its incorporation in 2006, Anterios has aimed to enhance the administration of drugs and cosmetics, particularly in the fields of medical dermatology and aesthetic medicine.

Northwood Medical Innovation

Founded in 2005, AqueSys specializes in developing and commercializing innovative ophthalmic devices. Its flagship product is the XEN gel stent, an implantable device designed to lower intraocular pressure by creating a new drainage pathway for excess fluid in glaucoma patients.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Oculeve is a MedTech start-up focused on addressing unmet clinical needs in ophthalmology, specifically the treatment of dry eye disease. The company has developed a first-in-class, non-invasive nasal neurostimulation device that aims to increase tear production in patients suffering from this condition. Founded with early investments from notable firms, Oculeve's innovative approach to treating dry eye has positioned it as a significant player in the healthcare landscape. In August 2015, the company was acquired by Allergan Plc, further expanding its reach and impact in the medical field.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

Exemplar is a pharmaceutical company that specializes in developing inhalation products for lungs, nasal passages, and buccal cavities.

Map Pharmaceuticals, Inc. is a development stage company based in Mountain View, California, specializing in the creation of novel inhalation therapies for respiratory and systemic diseases. Founded in 2003, the company is advancing several proprietary product candidates through clinical development. These include Unit Dose Budesonide, aimed at treating pediatric asthma in children aged six months to eight years, and MAP0004, which targets migraine relief. Additionally, the product portfolio features MAP0005 for the treatment of asthma and chronic obstructive pulmonary disease in adolescents and adults, as well as MAP0001, designed for pulmonary delivery of medications for Type 1 and Type 2 diabetes utilizing the Tempo inhaler. Map Pharmaceuticals is focused on improving treatment options for patients with various health conditions.

SkinMedica is a company dedicated to developing, acquiring, and commercializing products aimed at improving skin appearance. It specializes in both prescription and non-prescription skincare solutions marketed primarily to physicians and medical spas. The company's notable offerings include the TNS Essential Serum® and TNS Recovery Complex®, which are designed to enhance skin quality, reduce signs of aging, and deliver various skincare benefits. SkinMedica's prescription product, VANIQA® Cream, is the only FDA-approved treatment for the reduction of unwanted facial hair in women. Additionally, SkinMedica's portfolio includes a range of aesthetic skincare products, moisturizers, sun protection, and specialized treatments for conditions such as acne and sensitive skin. The company also features Colorescience Pro, a line of dermatologist-recommended cosmetics that address specific skin concerns while providing sun protection.

EMKinetics, Inc. is a clinical-stage medical technology company based in San Francisco, California, that specializes in developing neuromodulation therapies using its proprietary Transdermal Stimulation (TranStim) technology. The company focuses on innovative treatments for conditions such as overactive bladder and other related ailments, employing electric pulses to prevent urinary incontinence. Founded in 2006, EMKinetics is dedicated to advancing its therapeutic offerings through cutting-edge research and development in the field of neuromodulation.

Precision Light, Inc. is a medical device company specializing in the development and distribution of advanced imaging systems designed to simulate the outcomes of aesthetic medical procedures. The company focuses on creating innovative solutions for breast, facial, and body imaging, enabling patients and healthcare professionals to visualize the potential results of procedures such as breast surgery and other plastic surgeries. By providing realistic simulations, Precision Light aims to enhance patient satisfaction and decision-making in aesthetic treatments.

Vicept Therapeutics, Inc., located in Malvern, Pennsylvania, is a privately held specialty biopharmaceutical company established in August 2009. The company focuses on developing innovative topically applied therapies aimed at treating erythema, or skin redness, associated with rosacea and other dermatological conditions characterized by redness and flushing. In addition to its research and development efforts, Vicept manufactures and distributes dermatological therapeutic products, positioning itself as a key player in addressing the unmet needs of patients with these skin disorders.

Serica Technologies, Inc. is a medical device company based in Medford, Massachusetts, specializing in silk-based biomaterial platforms for tissue repair. The company develops innovative products, including SeriGel, a bioresorbable silk hydrogel for plastic and reconstructive surgery and drug delivery, and SeriFascia, a surgical scaffold implant that aids in restoring collagen tissue affected by surgery or aging. Additionally, Serica offers SeriACL, a biodegradable ligament graft for anterior cruciate ligament repair, SeriCuff for rotator cuff tendon repair, and SeriScaffold surgical mesh for repairing damaged connective tissues. The company's products serve various applications in orthopedics, sports medicine, and aesthetic and reconstructive surgery. Founded in 1998, Serica Technologies was previously known as Tissue Regeneration, Inc. and rebranded in 2006.

BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and headquartered in Goleta, California. The company specializes in developing non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is a device that is inserted into the stomach through the mouth using a straightforward endoscopic procedure. This device is designed to enhance the sensation of fullness by causing the stomach to fill up faster and remain full longer, while also delaying gastric emptying. Through its innovative approach, BAROnova seeks to provide patients with effective tools for weight management without the need for surgery.

Esprit Pharma is a pharmaceutical company focused on specialty therapeutics and committed to improving patient well-being in the urology and OB/GYN areas by providing products that contribute to bettering patient outcomes.

EndoArt is a synthetic implant that treats corneal edema by establishing a new form of corneal availability, hence protecting vision and restoring function.

A healthcare products manufacturer focused on marketing breast implants, dermal fillers to correct facial wrinkles.

Oculex Pharmaceuticals is an ophthalmic drug delivery company specializing in the development of therapeutic products aimed at treating sight-threatening diseases. Founded in 1989 and based in Sunnyvale, California, the company focuses on innovative solutions for conditions affecting the back of the eye, such as diabetic macular edema and age-related macular degeneration. Oculex has developed a proprietary biodegradable drug delivery technology that allows for the localized administration of medications directly within the eye. One of its key products, Posurdex, is a biodegradable implant that delivers dexamethasone to the targeted disease site, providing effective treatment for chronic eye conditions. In November 2003, Oculex Pharmaceuticals was acquired by Allergan.